Identification and management of tardive dyskinesia: A case series and literature review

Postgrad Med. 2015;127(7):726-37. doi: 10.1080/00325481.2015.1074031. Epub 2015 Jul 27.

Abstract

Tardive dyskinesia (TD) is a serious, disabling and potentially permanent, neurological hyperkinetic movement disorder that occurs after months or years of taking dopamine receptor-blocking agents. The pathophysiology of TD is complex, multifactorial and still not fully understood. Although there is no identified effective and standard treatment for TD, several agents have been tried for the management of this motor disturbance. The aim of this case series is to review the literature in regard to the identification, diagnosis and the treatment of TD with anticholinergics, anticholinergic medication withdrawal, cholinergic agents, botulinum toxin intramuscular injections, tetrabenazine, levetiracetam, propranolol and zolpidem, and to describe one case of TD that responded favorably to clonazepam and two cases of TD that responded favorably to Ginkgo biloba.

Keywords: Antipsychotics; Ginkgo biloba; clonazepam; psychopharmacology; tardive dyskinesia.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adult
  • Aged
  • Anti-Dyskinesia Agents / administration & dosage
  • Clonazepam / administration & dosage*
  • Diagnosis, Differential
  • Dopamine Antagonists / administration & dosage
  • Dopamine Antagonists / adverse effects
  • Dyskinesia, Drug-Induced / diagnosis
  • Dyskinesia, Drug-Induced / drug therapy
  • Dyskinesia, Drug-Induced / etiology
  • Female
  • Ginkgo biloba*
  • Heartburn / diagnosis
  • Heartburn / drug therapy*
  • Humans
  • Middle Aged
  • Movement Disorders* / diagnosis
  • Movement Disorders* / drug therapy
  • Movement Disorders* / etiology
  • Perphenazine / administration & dosage
  • Perphenazine / adverse effects*
  • Plant Extracts / administration & dosage*
  • Positron-Emission Tomography
  • Severity of Illness Index
  • Tomography, Emission-Computed, Single-Photon
  • Treatment Outcome

Substances

  • Anti-Dyskinesia Agents
  • Dopamine Antagonists
  • Plant Extracts
  • Clonazepam
  • Perphenazine